John R Eckardt
Overview
Explore the profile of John R Eckardt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
227
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arnold S, Rinehart J, Tsakalozou E, Eckardt J, Fields S, Shelton B, et al.
Clin Cancer Res
. 2010 Jan;
16(2):673-80.
PMID: 20068096
Purpose: 7-t-Butyldimethylsilyl-10-hydroxycamptothecin (AR-67) is a novel third generation camptothecin selected for development based on the blood stability of its pharmacologically active lactone form and its high potency in preclinical models....
2.
Eckardt J, Bentsion D, Lipatov O, Polyakov I, Mackintosh F, Karlin D, et al.
J Clin Oncol
. 2009 Mar;
27(12):2046-51.
PMID: 19289620
Purpose: This study was designed to confirm the efficacy and safety of picoplatin, a cisplatin analog designed to overcome platinum resistance, in patients with small-cell lung cancer (SCLC) with platinum-refractory/-resistant...
3.
Eckardt J, von Pawel J, Pujol J, Papai Z, Quoix E, Ardizzoni A, et al.
J Clin Oncol
. 2007 May;
25(15):2086-92.
PMID: 17513814
Purpose: Single-agent intravenous (IV) topotecan is an effective treatment for small-cell lung cancer (SCLC) after failure of first-line chemotherapy. This open-label, randomized, phase III study compared oral and IV topotecan...
4.
Eckardt J, von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts T, et al.
J Clin Oncol
. 2006 May;
24(13):2044-51.
PMID: 16648504
Purpose: This open-label, randomized, multicenter phase III study compared oral topotecan/intravenous cisplatin (TC) with intravenous (IV) etoposide/cisplatin (PE) in patients with untreated extensive-disease small-cell lung cancer (ED-SCLC). Patients And Methods:...
5.
Eckardt J
Oncologist
. 2004 Dec;
9 Suppl 6:25-32.
PMID: 15616147
Small cell lung cancer (SCLC) is an aggressive tumor that often metastasizes before the primary cancer is diagnosed. Patients with SCLC are typically elderly and often have comorbidities that may...
6.
Hammond L, Eckardt J, Kuhn J, Gerson S, Johnson T, Smith L, et al.
Clin Cancer Res
. 2004 Mar;
10(5):1645-56.
PMID: 15014015
Purpose: O(6)-alkylguanine-DNA alkyltransferase (AGAT) is modulated by methylating agents, which, in turn, abrogates nitrosourea resistance in preclinical studies. The feasibility of administering various sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide (TEM)...
7.
8.
Eckardt J
Oncology (Williston Park)
. 2003 Mar;
17(2):181-8, 191; discussion 191-2, passim.
PMID: 12632863
Small-cell lung cancer is an aggressive tumor associated with high rates of regional or distant metastases at diagnosis. Although highly chemosensitive to agents given in the first-line setting (e.g., etoposide...